New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C Patients Without Ribavirin
- Category: Experimental HCV Drugs
- Published on Monday, 24 October 2016 00:00
- Written by HIVandHepatitis.com
An investigational 3-drug coformulation from Gilead Sciences produced sustained virological response (SVR) in 95% to 98% of hard-to-treat hepatitis C patients in the Phase 3 POLARIS trials, including people who were previously treated with direct-acting antivirals and those with hepatitis C virus (HCV) genotype 3 and compensated cirrhosis, according to a recent company announcement. Gilead plans to request Food and Drug Administration approval of the new combination by the end of the year.